drugset / Trial / NCT00030654

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

NCT00030654

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as luteinizing hormone-releasing hormone agonist, flutamide, and bicalutamide may stop the adrenal glands from producing androgens. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. It is not yet known whether chemotherapy given at the same time as hormone therapy is more effective than chemotherapy given after hormone therapy in treating prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy given at the same time as hormone therapy with that of chemotherapy given after hormone therapy in treating patients who have prostate cancer.

Timeline

Start
2002-10
Primary completion
2005-02-04
Completion
2005-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject Doxorubicin Other / unclassified Intravenous
Subject Ketoconazole Small molecule Oral
Subject Paclitaxel Small molecule Intravenous
Subject Vinblastine Small molecule Intravenous
Subject estramustine Other / unclassified Oral
Background Bicalutamide Other / unclassified Oral
Background flutamide Small molecule Oral

Indications